With the help of sophisticated bioconjugation and radiolabeling techniques, numerous peptide-based agents have been developed and evaluated for delivery of PET radionuclides to the specific molecular targets in preclinical and clinical studies.
Interestingly and in support for this conclusion, platinum-based agents have been tested in patients with TNBC, and BRCA1 methylation was found to be predictive of response.
In addition, gene- and nucleic-acid-based agents have been developed as HIV-1 prophylactics, including RNA aptamers and siRNAs that are used as microbicides and viral genes used as vaccines (Table 1).
In the past, only two clinical-grade, iron-oxide-based agents have been developed and approved for MRI of the liver: (1) SPIO nanoparticles coated with dextran as a polysaccharide (i.e. ferumoxides, also known as Endorem® in Europe and Feridex® in the USA) and (2) SPIO nanoparticles coated with low molecular weight carboxydextran (i.e. ferucarbotran, also known as Resovist®).
To date, on these molecular bases, many agents have been included in clinical trials for patients with TNBC.
With the use of Traditional Chinese prescriptions and formulae, which are based on TCM principles, these agents have been identified as effective anti-cancer drugs in cancer patients, such as breast carcinoma, gastric cancer and colorectal cancer.
A series of pyridoxine-resveratrol hybrids Mannich base derivatives as multifunctional agents have been designed, synthesized and evaluated for cholinesterase (ChE) and monoamine oxidase (MAO) inhibitory activity.
Until recently, only few radiolabeled tetrazines mainly based on radiometals and bulky chelating agents have been reported.
Liposome based vaccine preparations specific for infectious agents have been successfully tested (Gluck, 1995).
